First Gene Therapy for Hemophilia B, CSL’s HEMGENIX, Approved by the European Commission
Global biotechnology leader CSL announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX (etranacogene dezaparvovec), the first and only…
Read More...
Read More...